BioGend Therapeutics Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 2, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	4,458	4,775	4,181	4,708	2,247	2,757
Market Cap Growth	9.89%	14.21%	-11.18%	109.50%	-18.50%	-22.86%
Enterprise Value	3,962	4,269	3,558	3,990	1,720	2,063
Last Close Price	35.85	38.28	33.55	38.13	21.73	26.32
PS Ratio	20.05	21.48	24.94	42.83	71.46	297.47
PB Ratio	5.88	6.30	4.94	4.92	3.07	2.92
P/TBV Ratio	6.84	7.33	6.09	6.09	4.73	4.53
EV/Sales Ratio	17.82	19.20	21.22	36.30	54.70	222.54
Debt / Equity Ratio	0.01	0.01	0.01	0.01	0.02	0.01
Net Debt / Equity Ratio	-0.67	-0.67	-0.72	-0.74	-0.65	-0.73
Net Debt / EBITDA Ratio	8.42	8.42	8.15	5.68	2.80	4.97
Net Debt / FCF Ratio	7.80	7.80	6.12	4.32	2.56	4.98
Asset Turnover	0.26	0.26	0.17	0.12	0.03	0.01
Inventory Turnover	3.41	3.41	2.29	1.89	1.24	0.64
Quick Ratio	16.02	16.02	21.06	16.90	16.73	28.58
Current Ratio	17.60	17.60	21.60	17.32	17.01	29.24
Return on Equity (ROE)	-11.88%	-11.88%	-13.30%	-19.07%	-24.54%	-17.51%
Return on Assets (ROA)	-7.99%	-7.99%	-7.78%	-11.79%	-14.85%	-11.74%
Return on Capital Employed (ROCE)	-14.20%	-14.20%	-13.90%	-17.60%	-27.70%	-16.50%
Earnings Yield	-1.90%	-1.77%	-2.79%	-3.32%	-8.21%	-5.02%
FCF Yield	-1.47%	-1.37%	-2.38%	-3.50%	-8.32%	-4.99%
Buyback Yield / Dilution	0.37%	0.37%	-2.32%	-16.69%	-1.77%	-15.90%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.